TBC1D3 Antibody

TBC1D3 Antibody Generation and Validation

TBC1D3 antibodies are typically raised against specific peptide regions of the protein to ensure target specificity. Key characteristics include:

These antibodies have been rigorously validated in studies demonstrating TBC1D3's role in basal progenitor generation in human brain slices and macropinocytosis regulation .

Neural Development

• TBC1D3 promotes the generation of outer radial glial (oRG) cells, which are critical for cortical expansion in primates. siRNA-mediated TBC1D3 knockdown in human fetal brain slices reduced Sox2+ basal progenitors by 50–70%, rescued by TBC1D3 co-expression .

• In transgenic mice, TBC1D3 expression increased basal progenitor proliferation, mimicking primate-specific neurogenesis .

Oncogenic Signaling

• TBC1D3 enhances EGFR signaling by delaying receptor degradation, prolonging Erk and Akt activation. Overexpression increases EGFR levels by 50% and thymidine incorporation by 2.5-fold in DU145 prostate cancer cells .

• Confocal microscopy revealed prolonged EGFR retention in EEA1-negative endosomes in TBC1D3-expressing cells, correlating with enhanced cell proliferation .

Membrane Trafficking

• TBC1D3 antibodies identified interactions with ARF6 and GGA3, essential for macropinocytosis. Co-immunoprecipitation assays showed TBC1D3-GGA3 complexes localize to ARF6-induced endosomes .

• Deletion mutants lacking the N-terminal region (aa 2–92) disrupted GGA3 binding, impairing fluid-phase uptake by 60% .

Functional Insights from Antibody-Based Studies

Technical Considerations

• Specificity Challenges: Due to TBC1D3’s homology with eight paralogs on chromosome 17, antibodies must target non-conserved regions (e.g., C-terminal epitopes) .

• Species Limitations: TBC1D3 is absent in non-primate models, necessitating human-derived samples or transgenic systems for functional studies .

Emerging Applications

• Cancer Therapeutics: Targeting TBC1D3’s role in EGFR stabilization could sensitize tumors to tyrosine kinase inhibitors .

• Neurodevelopmental Disorders: Aberrant TBC1D3 expression may contribute to microcephaly or megalencephaly via dysregulated oRG proliferation .